FinscoFinsco

Castle Biosciences (US.CSTL)

Capital Allocation Audit · Period: 2017 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CSTL · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion404.6%↑
ROE-3.5%↑
Cash Conversion-→
D/E Ratio0.08→
Gross Margin76.4%↓
US.CSTL (Castle Biosciences) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   404.6%    ↑
ROE               -3.5%    ↑
Cash Conversion       -    →
D/E Ratio          0.08    →
Gross Margin      76.4%    ↓
Key Metrics
US.CSTL (Castle Biosciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 404.6% ↑
ROE -3.5% ↑
Cash Conversion - →
D/E Ratio 0.08 →
Gross Margin 76.4% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies